Hormonal
Intensive glycemic therapy (targeting near-normal glucose levels) significantly reduces the development and progression of microvascular complications (retinopathy, nephropathy, neuropathy) and cardiovascular disease in patients with type 1 diabetes compared to conventional therapy.
For people with Type 1 Diabetes, aiming for near-normal blood sugar levels through intensive insulin therapy (multiple daily injections or a pump) significantly reduces the risk of eye, kidney, nerve, and heart complications over the long term. While this approach increases the risk of low blood sugar events, it does not harm cognitive function or quality of life. The key is individualizing the regimen to fit your lifestyle while striving for lower HbA1c targets.
The DCCT/EDIC convincingly demonstrated that the glucose hypothesis was correct and that an intervention that aimed to achieve glycemia as close to the nondiabetic range as safely possible reduced all of the microvascular and cardiovascular complications of diabetes.
Why this rating
The DCCT/EDIC is a landmark, long-term (30 years), randomized controlled trial with high follow-up rates and objective outcome measures.
Source
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
David M. Nathan · Diabetes Care · 2013
DOI 10.2337/dc13-2112
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →